{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:20Z","timestamp":1761016940485,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.eplepsyres.2012.03.007","type":"journal-article","created":{"date-parts":[[2012,4,17]],"date-time":"2012-04-17T22:46:12Z","timestamp":1334702772000},"page":"92-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: A double-blind, randomised, multicentre, historical control study"],"prefix":"10.1016","volume":"101","author":[{"given":"Steve","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo","family":"Ceja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Gaw\u0142owicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagik","family":"Avakyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"McShea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"Schiemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1684\/j.1950-6945.2003.tb00001.x","article-title":"Rational conversion from antiepileptic polytherapy to monotherapy","volume":"5","author":"Baulac","year":"2003","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0010","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000mg\/day in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0015","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1212\/01.wnl.0000268699.34614.d3","article-title":"Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy; Levetiracetam N01057 Study Group","volume":"69","author":"Berkovic","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0020","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000252941.50833.4a","article-title":"Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy","volume":"68","author":"Brodie","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0025","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.seizure.2005.01.008","article-title":"Complaints associated with the use of antiepileptic drugs: results from a community-based study","volume":"14","author":"Carpay","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0030","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0035","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1212\/01.wnl.0000302370.01359.8f","article-title":"Monotherapy in adults and elderly persons","volume":"69","author":"Faught","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0040","unstructured":"French, J.A., Wang, S., Warnock, B., Temkin, N. Alternative monotherapy design in the treatment of epilepsy [White paper], 2009."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0045","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1528-1167.2010.02650.x","article-title":"Historical control monotherapy design in the treatment of epilepsy","volume":"51","author":"French","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0050","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.51.4.1018","article-title":"An active-control trial of lamotrigine monotherapy for partial seizures","volume":"51","author":"Gilliam","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0055","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0060","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1532-5415.2005.53323.x","article-title":"Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home","volume":"53","author":"Harms","year":"2005","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1528-1157.1981.tb06159.x","article-title":"Proposal for revised clinical and electroencephalographic classification of epileptic seizures. From the Commission on Classification and Terminology of the International League Against Epilepsy","volume":"22","author":"International League Against","year":"1981","journal-title":"Epilepsia"},{"issue":"Suppl. 7","key":"10.1016\/j.eplepsyres.2012.03.007_bib0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1528-1157.44.s7.7.x","article-title":"Issues in clinical trial design from the FDA perspective","volume":"44","author":"Katz","year":"2003","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0075","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2005.09.034","article-title":"FDA update","volume":"68","author":"Katz","year":"2006","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0080","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/WCO.0b013e3283292427","article-title":"Interpreting regulatory trials in epilepsy","volume":"22","author":"Marson","year":"2009","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0090","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM198507183130303","article-title":"Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic\u2013clonic seizures","volume":"313","author":"Mattson","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0095","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1212\/01.wnl.0000297512.18364.40","article-title":"Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures","volume":"70","author":"Noachtar","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0105","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0110","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1535-7511.2009.01326.x","article-title":"Extended-release formulations of antiepileptic drugs: rationale and comparative value","volume":"9","author":"Perucca","year":"2009","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0115","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0920-1211(98)00095-3","article-title":"Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications","volume":"33","author":"Perucca","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0120","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.clinthera.2010.09.017","article-title":"Adjunctive levetiracetam in patients aged 1 month to <4 years with partial-onset seizures: sub-population analysis of a prospective, open-label extension study up to 48 weeks","volume":"32","author":"Pi\u00f1a-Garza","year":"2010","journal-title":"Clin. Ther."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0125","series-title":"62nd Annual Meeting of the American Epilepsy Society","article-title":"The KOMET study: an open-label, randomized, parallel-group trial comparing the efficacy and safety of levetiracetam with sodium valproate and carbamazepine as monotherapy in subjects with newly diagnosed epilepsy","author":"Pohlmann-Eden","year":"2008"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.yebeh.2009.07.013","article-title":"Levetiracetam extended release and levetiracetam immediate release as adjunctive treatment for partial-onset seizures: an indirect comparison of treatment-emergent adverse events using meta-analytic techniques","volume":"16","author":"Richy","year":"2009","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0135","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.eplepsyres.2009.02.001","article-title":"Pharmacokinetics of levetiracetam XR 500mg tablets","volume":"84","author":"Rouits","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1212\/WNL.57.5.864","article-title":"Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures","volume":"57","author":"Sachdeo","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0145","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/0883073811417183","article-title":"A long-term open-label extension study assessing cognition and behavior, tolerability, safety, and efficacy of adjunctive levetiracetam in children aged 4\u201316 years with partial-onset seizures","volume":"27","author":"Schiemann-Delgado","year":"2012","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0150","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2012.03.007_bib0155","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/157015909788848866","article-title":"Antiepileptic drug monotherapy: the initial approach in epilepsy management","volume":"7","author":"St Louis","year":"2009","journal-title":"Curr. Neuropharmacol."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112000824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121112000824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:27:02Z","timestamp":1760275622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121112000824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":31,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0920121112000824"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.03.007","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: A double-blind, randomised, multicentre, historical control study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2012.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}